home · filing · 0001193125-21-300558
8-K filed October 18, 2021, 7:59 PM ET
ticker CGEM
CIK 0001789972
leadership
confidence high
sentiment neutral
materiality 0.70
Cullinan Oncology CEO Owen Hughes departs; Nadim Ahmed appointed as new President and CEO
Cullinan Therapeutics, Inc.
CEO Owen Hughes departs Oct 18, 2021; gets 12 months base salary, pro-rata bonus of $216,507, and accelerated vesting.
Nadim Ahmed appointed CEO, President, and Board member effective Oct 18; previously President of Hematology at BMS.
Ahmed receives $600k base salary, $625k sign-on bonus, 2.71M stock options, and performance RSUs.
Hughes will serve as Strategic Advisor for up to 12 months; noncompetition and nondisclosure covenants apply.
Company reaffirms Pearl update expected in Q4 2021; no change to pipeline plans.
Executive movements
Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements .
Effective 2021-10-18
Successor Nadim Ahmed
Filed October 18, 2021, 7:59 PM ET
Mr. Hughes’ last date of employment with the Company as its President and Chief Executive Officer is October 18, 2021
Effective 2021-10-18
Filed October 18, 2021, 7:59 PM ET
the Board appointed Mr. Ahmed as a Class III director of the Company, effective as of October 18, 2021
Effective 2021-10-18
Filed October 18, 2021, 7:59 PM ET
the Board appointed Nadim Ahmed as President and Chief Executive Officer of the Company, effective as of October 18, 2021
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Owen Hughes departed as President and Chief Executive Officer at Cullinan Therapeutics, Inc..
Action departed
Role President and Chief Executive Officer
Exact text from the filing
Mr. Hughes’ last date of employment with the Company as its President and Chief Executive Officer is October 18, 2021
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Nadim Ahmed was appointed as Class III Director at Cullinan Therapeutics, Inc..
Action appointed
Role Class III Director
Exact text from the filing
the Board appointed Mr. Ahmed as a Class III director of the Company, effective as of October 18, 2021
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Nadim Ahmed was appointed as President and Chief Executive Officer at Cullinan Therapeutics, Inc..
Action appointed
Role President and Chief Executive Officer
Exact text from the filing
the Board appointed Nadim Ahmed as President and Chief Executive Officer of the Company, effective as of October 18, 2021
View on SEC.gov
Source: SEC EDGAR
accession 0001193125-21-300558
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.